Global Dihydropyridine Calcium Channel Blockers Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08257010

Publication Date:

August 11, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Dihydropyridine Calcium Channel Blockers market size will reach US$ 1744 million by 2031.
Dihydropyridine calcium channel blockers (DHP-CCBs) are a class of medications that selectively inhibit L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. They are primarily used to treat hypertension and angina pectoris. Common agents include amlodipine, nifedipine, and felodipine. DHP-CCBs are known for their strong effect on peripheral vasodilation with minimal impact on cardiac conduction, making them distinct from non-dihydropyridine calcium channel blockers.
United States market for Dihydropyridine Calcium Channel Blockers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Dihydropyridine Calcium Channel Blockers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Dihydropyridine Calcium Channel Blockers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Dihydropyridine Calcium Channel Blockers players cover Bayer, Huanghai Pharma, Shyndec Pharma, Beijing Hongling Pharma, Ingenus Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒ihydropyridine Calcium Channel Blockers Industry Forecast鈥� looks at past sales and reviews total world Dihydropyridine Calcium Channel Blockers sales in 2024, providing a comprehensive analysis by region and market sector of projected Dihydropyridine Calcium Channel Blockers sales for 2025 through 2031. With Dihydropyridine Calcium Channel Blockers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dihydropyridine Calcium Channel Blockers industry.
This Insight Report provides a comprehensive analysis of the global Dihydropyridine Calcium Channel Blockers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dihydropyridine Calcium Channel Blockers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Dihydropyridine Calcium Channel Blockers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dihydropyridine Calcium Channel Blockers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dihydropyridine Calcium Channel Blockers.
This report presents a comprehensive overview, market shares, and growth opportunities of Dihydropyridine Calcium Channel Blockers market by product type, application, key players and key regions and countries.
Segmentation by Type:
Nifedipine
Iradipine
Felodipine
Nicardipine
Other
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Huanghai Pharma
Shyndec Pharma
Beijing Hongling Pharma
Ingenus Pharmaceutical
Sine Pharma
AstraZeneca
Lifeon Pharma
Teva
Nanjing Easeheal Pharma
Novartis
Baxter International
Hikma Pharmaceuticals
Astellas Pharma
Aguettant

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dihydropyridine Calcium Channel Blockers Market Size (2020-2031)
2.1.2 Dihydropyridine Calcium Channel Blockers Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Dihydropyridine Calcium Channel Blockers by Country/Region (2020, 2024 & 2031)
2.2 Dihydropyridine Calcium Channel Blockers Segment by Type
2.2.1 Nifedipine
2.2.2 Iradipine
2.2.3 Felodipine
2.2.4 Nicardipine
2.2.5 Other
2.3 Dihydropyridine Calcium Channel Blockers Market Size by Type
2.3.1 Dihydropyridine Calcium Channel Blockers Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Dihydropyridine Calcium Channel Blockers Market Size Market Share by Type (2020-2025)
2.4 Dihydropyridine Calcium Channel Blockers Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Dihydropyridine Calcium Channel Blockers Market Size by Application
2.5.1 Dihydropyridine Calcium Channel Blockers Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Dihydropyridine Calcium Channel Blockers Market Size Market Share by Application (2020-2025)
3 Dihydropyridine Calcium Channel Blockers Market Size by Player
3.1 Dihydropyridine Calcium Channel Blockers Market Size Market Share by Player
3.1.1 Global Dihydropyridine Calcium Channel Blockers Revenue by Player (2020-2025)
3.1.2 Global Dihydropyridine Calcium Channel Blockers Revenue Market Share by Player (2020-2025)
3.2 Global Dihydropyridine Calcium Channel Blockers Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Dihydropyridine Calcium Channel Blockers by Region
4.1 Dihydropyridine Calcium Channel Blockers Market Size by Region (2020-2025)
4.2 Global Dihydropyridine Calcium Channel Blockers Annual Revenue by Country/Region (2020-2025)
4.3 Americas Dihydropyridine Calcium Channel Blockers Market Size Growth (2020-2025)
4.4 APAC Dihydropyridine Calcium Channel Blockers Market Size Growth (2020-2025)
4.5 Europe Dihydropyridine Calcium Channel Blockers Market Size Growth (2020-2025)
4.6 Middle East & Africa Dihydropyridine Calcium Channel Blockers Market Size Growth (2020-2025)
5 Americas
5.1 Americas Dihydropyridine Calcium Channel Blockers Market Size by Country (2020-2025)
5.2 Americas Dihydropyridine Calcium Channel Blockers Market Size by Type (2020-2025)
5.3 Americas Dihydropyridine Calcium Channel Blockers Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dihydropyridine Calcium Channel Blockers Market Size by Region (2020-2025)
6.2 APAC Dihydropyridine Calcium Channel Blockers Market Size by Type (2020-2025)
6.3 APAC Dihydropyridine Calcium Channel Blockers Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Dihydropyridine Calcium Channel Blockers Market Size by Country (2020-2025)
7.2 Europe Dihydropyridine Calcium Channel Blockers Market Size by Type (2020-2025)
7.3 Europe Dihydropyridine Calcium Channel Blockers Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dihydropyridine Calcium Channel Blockers by Region (2020-2025)
8.2 Middle East & Africa Dihydropyridine Calcium Channel Blockers Market Size by Type (2020-2025)
8.3 Middle East & Africa Dihydropyridine Calcium Channel Blockers Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Dihydropyridine Calcium Channel Blockers Market Forecast
10.1 Global Dihydropyridine Calcium Channel Blockers Forecast by Region (2026-2031)
10.1.1 Global Dihydropyridine Calcium Channel Blockers Forecast by Region (2026-2031)
10.1.2 Americas Dihydropyridine Calcium Channel Blockers Forecast
10.1.3 APAC Dihydropyridine Calcium Channel Blockers Forecast
10.1.4 Europe Dihydropyridine Calcium Channel Blockers Forecast
10.1.5 Middle East & Africa Dihydropyridine Calcium Channel Blockers Forecast
10.2 Americas Dihydropyridine Calcium Channel Blockers Forecast by Country (2026-2031)
10.2.1 United States Market Dihydropyridine Calcium Channel Blockers Forecast
10.2.2 Canada Market Dihydropyridine Calcium Channel Blockers Forecast
10.2.3 Mexico Market Dihydropyridine Calcium Channel Blockers Forecast
10.2.4 Brazil Market Dihydropyridine Calcium Channel Blockers Forecast
10.3 APAC Dihydropyridine Calcium Channel Blockers Forecast by Region (2026-2031)
10.3.1 China Dihydropyridine Calcium Channel Blockers Market Forecast
10.3.2 Japan Market Dihydropyridine Calcium Channel Blockers Forecast
10.3.3 Korea Market Dihydropyridine Calcium Channel Blockers Forecast
10.3.4 Southeast Asia Market Dihydropyridine Calcium Channel Blockers Forecast
10.3.5 India Market Dihydropyridine Calcium Channel Blockers Forecast
10.3.6 Australia Market Dihydropyridine Calcium Channel Blockers Forecast
10.4 Europe Dihydropyridine Calcium Channel Blockers Forecast by Country (2026-2031)
10.4.1 Germany Market Dihydropyridine Calcium Channel Blockers Forecast
10.4.2 France Market Dihydropyridine Calcium Channel Blockers Forecast
10.4.3 UK Market Dihydropyridine Calcium Channel Blockers Forecast
10.4.4 Italy Market Dihydropyridine Calcium Channel Blockers Forecast
10.4.5 Russia Market Dihydropyridine Calcium Channel Blockers Forecast
10.5 Middle East & Africa Dihydropyridine Calcium Channel Blockers Forecast by Region (2026-2031)
10.5.1 Egypt Market Dihydropyridine Calcium Channel Blockers Forecast
10.5.2 South Africa Market Dihydropyridine Calcium Channel Blockers Forecast
10.5.3 Israel Market Dihydropyridine Calcium Channel Blockers Forecast
10.5.4 Turkey Market Dihydropyridine Calcium Channel Blockers Forecast
10.6 Global Dihydropyridine Calcium Channel Blockers Forecast by Type (2026-2031)
10.7 Global Dihydropyridine Calcium Channel Blockers Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Dihydropyridine Calcium Channel Blockers Forecast
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Dihydropyridine Calcium Channel Blockers Product Offered
11.1.3 Bayer Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Huanghai Pharma
11.2.1 Huanghai Pharma Company Information
11.2.2 Huanghai Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.2.3 Huanghai Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Huanghai Pharma Main Business Overview
11.2.5 Huanghai Pharma Latest Developments
11.3 Shyndec Pharma
11.3.1 Shyndec Pharma Company Information
11.3.2 Shyndec Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.3.3 Shyndec Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Shyndec Pharma Main Business Overview
11.3.5 Shyndec Pharma Latest Developments
11.4 Beijing Hongling Pharma
11.4.1 Beijing Hongling Pharma Company Information
11.4.2 Beijing Hongling Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.4.3 Beijing Hongling Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Beijing Hongling Pharma Main Business Overview
11.4.5 Beijing Hongling Pharma Latest Developments
11.5 Ingenus Pharmaceutical
11.5.1 Ingenus Pharmaceutical Company Information
11.5.2 Ingenus Pharmaceutical Dihydropyridine Calcium Channel Blockers Product Offered
11.5.3 Ingenus Pharmaceutical Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Ingenus Pharmaceutical Main Business Overview
11.5.5 Ingenus Pharmaceutical Latest Developments
11.6 Sine Pharma
11.6.1 Sine Pharma Company Information
11.6.2 Sine Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.6.3 Sine Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sine Pharma Main Business Overview
11.6.5 Sine Pharma Latest Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Information
11.7.2 AstraZeneca Dihydropyridine Calcium Channel Blockers Product Offered
11.7.3 AstraZeneca Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 AstraZeneca Main Business Overview
11.7.5 AstraZeneca Latest Developments
11.8 Lifeon Pharma
11.8.1 Lifeon Pharma Company Information
11.8.2 Lifeon Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.8.3 Lifeon Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Lifeon Pharma Main Business Overview
11.8.5 Lifeon Pharma Latest Developments
11.9 Teva
11.9.1 Teva Company Information
11.9.2 Teva Dihydropyridine Calcium Channel Blockers Product Offered
11.9.3 Teva Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Teva Main Business Overview
11.9.5 Teva Latest Developments
11.10 Nanjing Easeheal Pharma
11.10.1 Nanjing Easeheal Pharma Company Information
11.10.2 Nanjing Easeheal Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.10.3 Nanjing Easeheal Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Nanjing Easeheal Pharma Main Business Overview
11.10.5 Nanjing Easeheal Pharma Latest Developments
11.11 Novartis
11.11.1 Novartis Company Information
11.11.2 Novartis Dihydropyridine Calcium Channel Blockers Product Offered
11.11.3 Novartis Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Novartis Main Business Overview
11.11.5 Novartis Latest Developments
11.12 Baxter International
11.12.1 Baxter International Company Information
11.12.2 Baxter International Dihydropyridine Calcium Channel Blockers Product Offered
11.12.3 Baxter International Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Baxter International Main Business Overview
11.12.5 Baxter International Latest Developments
11.13 Hikma Pharmaceuticals
11.13.1 Hikma Pharmaceuticals Company Information
11.13.2 Hikma Pharmaceuticals Dihydropyridine Calcium Channel Blockers Product Offered
11.13.3 Hikma Pharmaceuticals Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Hikma Pharmaceuticals Main Business Overview
11.13.5 Hikma Pharmaceuticals Latest Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Information
11.14.2 Astellas Pharma Dihydropyridine Calcium Channel Blockers Product Offered
11.14.3 Astellas Pharma Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Astellas Pharma Main Business Overview
11.14.5 Astellas Pharma Latest Developments
11.15 Aguettant
11.15.1 Aguettant Company Information
11.15.2 Aguettant Dihydropyridine Calcium Channel Blockers Product Offered
11.15.3 Aguettant Dihydropyridine Calcium Channel Blockers Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Aguettant Main Business Overview
11.15.5 Aguettant Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂